Metraipolis › archive › dc_56ea7bbc5a35

Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report — Europe PMC PMID:41846922

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41846922
DOI
10.3389/fimmu.2026.1721711
License (as archived)
solo-consultazione
Archived
2026-11-05T10:04:56.494Z
SHA-256 of the archived text
003e2ebdbe71e5a054989aad1c9635cbb52ba33ff740442b1a03add58ff99cb2
Stable URL of this page
https://metraipolis.com/documento/dc_56ea7bbc5a35

How to cite

Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report — Europe PMC PMID:41846922 — Europe PMC (en), https://europepmc.org/article/MED/41846922 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_56ea7bbc5a35 (Metraipolis archive dc_56ea7bbc5a35, sha256 003e2ebdbe71e5a054989aad1c9635cbb52ba33ff740442b1a03add58ff99cb2)
BibTeX
@misc{dc56ea7bbc5a35,
  title = {Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report — Europe PMC PMID:41846922},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41846922},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_56ea7bbc5a35; sha256 003e2ebdbe71e5a054989aad1c9635cbb52ba33ff740442b1a03add58ff99cb2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41846922. Agents can read the archived copy with the MCP tool read_document.